Exosomal PD-L1 in hepatocellular carcinoma: Immune evasion mechanisms, diagnostic value, and strategies for therapeutic targeting.
Immune-evading particles in blood offer clues about liver cancer behavior and potential targets for immunotherapy, bridging diagnosis and treatment.
This review examines the role of exosomal PD-L1 in hepatocellular carcinoma, covering immune evasion mechanisms, diagnostic potential, and therapeutic targeting strategies. The work synthesizes an emerging area at the intersection of immunotherapy and liquid biopsy.
What the study was
- Study design
- Review
- Population
- HCC patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biomedicine & Pharmacotherapy
Why it surfaced
Review covering immunotherapy biomarker and therapeutic target in HCC. No primary data but comprehensive synthesis. Recovered from deferred PMIDs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.